Chapter title |
A review of clinical studies of bestatin.
|
---|---|
Chapter number | 20 |
Book title |
Cancer Chemo- and Immunopharmacology
|
Published in |
Recent results in cancer research Fortschritte der Krebsforschung Progrès dans les recherches sur le cancer, January 1980
|
DOI | 10.1007/978-3-642-81491-4_20 |
Pubmed ID | |
Book ISBNs |
978-3-64-281493-8, 978-3-64-281491-4
|
Authors |
Oka, S, S. Oka, Oka, S. |
Abstract |
Bestatin has no clinical toxicity. It increases the number of T cells and enhances NK cell activity. The optimal dose of bestatin was thought to range from 30-100 mg/day/body, and 200 mg/day/body often decreased T-cell number. The clinical effects were as follows: 1) Bestatin alone: possible cure in one case of residual penile tumor after bleomycin treatment; marked regression in two cases of skin metastasis of mammary carcinoma. 2) Radiation and bestatin: complete regression in three cases of Virchow's nodes. 3) Pepleomycin and bestatin: complete regression in one case of metastatic skin adenocarcinoma. 4) Possible favorable effect of bestatin against esophageal carcinoma in combination with radiation and bleomycin. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 10 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 3 | 30% |
Student > Ph. D. Student | 2 | 20% |
Student > Bachelor | 1 | 10% |
Other | 1 | 10% |
Student > Doctoral Student | 1 | 10% |
Other | 1 | 10% |
Unknown | 1 | 10% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 6 | 60% |
Agricultural and Biological Sciences | 1 | 10% |
Biochemistry, Genetics and Molecular Biology | 1 | 10% |
Unknown | 2 | 20% |